JPRN-jRCTs031210062进行中(未招募)2 期
GM-CSF Inhalation for Nontuberculous Mycobacterial Lung Disease Pilot Trial
Kikuchi Toshiaki0 个研究点目标入组 15 人开始时间: 2021年4月30日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable(—)
- 性别
- All
入选标准
- •Subjects meeting all of the conditions below:
- •1. Age 20 or more at the time of obtaining informed consent, regardless of gender
- •2. Information about the name and condition of the disease is appropriately provided in advance
- •3. Ability to understand the explanation of this trial and give written voluntary consent
- •4. Meet the diagnostic criteria of nontuberculous mycobacterial lung disease. , , and Mycobacterium avium or M. intracellulare is detected in sputum twice within 2 years.
- •5. Meet a) or b) below:
- •a) Sustained positive mycobacterial culture test after chemotherapy against nontuberculous mycobacterial lung disease for 6 months or more.
- •b) Withdrawal of chemotherapy against nontuberculous mycobacterial lung disease due to insufficient effectiveness or adverse effects 28 days or more before assessment for eligibility
排除标准
- •Subjects meeting one or more conditions below:
- •1. 12000/mm3 or more of WBC on enrollment
- •2. Previously treated with GM-CSF inhalation
- •3. 60 ml or more per 24 hours of Hemoptysis within 4 weeks
- •4. Cardiovascular diseases, congestive heart failure/angina pectoris/hemorrhagic diathesis etc., with severe symptoms
- •5. History of malignant tumor with in 5 years except treated uterine carcinoma in situ and local basal cell carcinoma
- •6. Systemic corticosteroid therapy with 10 mg/day or more on a prednisolone conversion basis within 3 months or the therapy is expected during this trial
- •7. Change of chemotherapy regimen against nontuberculous mycobacterial lung disease wihtin 28 days
- •8. Pregnancy, breast-feeding, or desire for childbearing during this trial
- •9. Liver dysfunction
- •10. Renal dysfunction
- •11. History of severe or unexplainable adverse effect by inhalatoin therapy
- •12. Incapable of informed consent, subject whose informed consent may not be voluntary
- •13. Ineligible for this trial at the medical discretion of the principal investigator
研究者
相似试验
尚未招募
Unknown
on Tubercular Mycobacteria Disease at AVBRH: A Clinical OverviewCTRI/2023/10/058524Jawaharlal Nehru Medical College Sawangi Meghe
已完成
不适用
Observational study for nontuberculous mycobacterial lung disease and non-cystic fibrosis bronchiectasisJPRN-UMIN000026487Keio University School of Medicine1,000
招募中
Unknown
Diagnosis of pulmonary nontuberculous mycobacterial infection using bronchoalveolar lavage fluid: A prospective studyPulmonary nontuberculous mycobacterial infectionJPRN-UMIN000051177Hosoya hospital40
已完成
2 期
A Phase II Study of Inhaled GM-CSF in Patients With Idiopathic Pulmonary Alveolar Proteinosis (iPAP)Idiopathic pulmonary alveolar proteinosisJPRN-jRCT1091220013Koh Nakata, M.D., Ph.D.Bioscience Medical Research Center (BMRC), Niigata University Medical & Dental Hospital40
已完成
不适用
Prospective cohort study of Nontuberculous mycobacteriosis, especially M. intracelluare.ontuberculous mycobacteriosisJPRN-UMIN000012029Fukuoka University Hospital100
